Sideroblastic Anemia and Pancytopenia

Relationship Between Sideroblastic Anemia and Pancytopenia

The World Health Organization (WHO) recommends that cases with pancytopenia and features of sideroblastic anemia should be classified as MDS-unclassified (MDS-U) rather than simple sideroblastic anemia 1
Pure sideroblastic anemia (Refractory Anemia with Ring Sideroblasts - RARS) typically presents with isolated anemia rather than pancytopenia, according to the WHO classification 2, 3
When pancytopenia is present with ring sideroblasts, this suggests a more complex myelodysplastic process rather than simple sideroblastic anemia, as indicated by the WHO classification 1

Sideroblastic anemia with pancytopenia typically indicates involvement of multiple hematopoietic cell lines, suggesting a clonal stem cell disorder rather than an isolated erythroid abnormality 4

The presence of ≥15% ring sideroblasts in erythroid precursors is diagnostic of sideroblastic anemia, but the overall diagnosis depends on whether other cell lines show dysplasia, according to the WHO classification 5, 1
Cytogenetic studies are crucial as specific abnormalities may help confirm MDS diagnosis in cases with pancytopenia, as recommended by the WHO 1
Flow cytometry may reveal aberrant phenotypic features in multiple cell lines, supporting a diagnosis of MDS rather than isolated sideroblastic anemia 2

Refractory Anemia with Ring Sideroblasts (RARS): Presents with anemia only, ≥15% ring sideroblasts, and erythroid dysplasia only, according to the WHO classification 2, 5
MDS-Unclassified (MDS-U): Includes cases with pancytopenia and unilineage dysplasia, which could include sideroblastic features, as defined by the WHO classification 2, 1

The presence of pancytopenia in a patient with sideroblastic features indicates a worse prognosis compared to isolated sideroblastic anemia, according to the WHO classification 1
Patients with pancytopenia and sideroblastic features may be at higher risk for progression to acute myeloid leukemia, especially if excess blasts are present, as indicated by the WHO classification 5
Treatment approaches differ significantly between isolated sideroblastic anemia and MDS with pancytopenia - the latter may require more aggressive interventions like hypomethylating agents, as recommended by the WHO 1